|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
JP7808058B2
(ja)
|
2020-06-02 |
2026-01-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
WO2023099624A1
(en)
|
2021-12-01 |
2023-06-08 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
CA3243798A1
(en)
|
2022-02-09 |
2023-08-17 |
Quanta Therapeutics, Inc. |
Kras Modulators and Their Uses
|
|
WO2023230190A1
(en)
|
2022-05-25 |
2023-11-30 |
Quanta Therapeutics, Inc. |
Pyrimidine based modulators and uses thereof
|
|
KR20260041941A
(ko)
|
2023-03-15 |
2026-03-27 |
콴타 테라퓨틱스, 인크. |
Kras 조절 인자 및 이의 용도
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ｒａｓ相關疾病或病症之組合療法
|
|
WO2024246099A1
(en)
*
|
2023-05-30 |
2024-12-05 |
Boehringer Ingelheim International Gmbh |
Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
WO2024255795A1
(en)
*
|
2023-06-14 |
2024-12-19 |
Insilico Medicine Ip Limited |
Kras inhibitors and uses thereof
|
|
WO2025016899A1
(en)
|
2023-07-19 |
2025-01-23 |
Bayer Aktiengesellschaft |
Spirocyclic compounds for the treatment of cancer
|
|
WO2025026903A1
(en)
|
2023-07-31 |
2025-02-06 |
Bayer Aktiengesellschaft |
Imidazo pyrimidine compounds for the treatment of cancer
|
|
CN121620514A
(zh)
|
2023-08-02 |
2026-03-06 |
耐瑞欧医疗公司 |
蛋白质酪氨酸磷酸酶降解剂及其用途
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
AU2024361909A1
(en)
|
2023-10-20 |
2026-03-26 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
US20250205238A1
(en)
|
2023-12-20 |
2025-06-26 |
Boehringer Ingelheim International Gmbh |
Anti-cancer combination therapy
|
|
CN117946135A
(zh)
*
|
2024-01-24 |
2024-04-30 |
上海湃隆生物科技有限公司 |
杂环类化合物、药物组合物及其应用
|
|
CN117924327A
(zh)
*
|
2024-01-24 |
2024-04-26 |
上海湃隆生物科技有限公司 |
具有大环结构的Kras抑制剂化合物
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025190158A1
(zh)
*
|
2024-03-14 |
2025-09-18 |
四川科伦博泰生物医药股份有限公司 |
螺环化合物、其制备方法及用途
|
|
WO2025190342A1
(zh)
*
|
2024-03-15 |
2025-09-18 |
苏州浦合医药科技有限公司 |
螺环化合物作为kras突变体抑制剂
|
|
WO2025201480A1
(zh)
*
|
2024-03-28 |
2025-10-02 |
苏州浦合医药科技有限公司 |
螺环化合物作为kras突变体抑制剂
|
|
TW202547461A
(zh)
|
2024-05-17 |
2025-12-16 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025261393A1
(en)
*
|
2024-06-19 |
2025-12-26 |
Insilico Medicine Ip Limited |
Novel compounds as kras inhibitors and uses thereof
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026007740A1
(zh)
*
|
2024-07-04 |
2026-01-08 |
四川科伦博泰生物医药股份有限公司 |
螺环化合物、其制备方法及用途
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015785A1
(en)
*
|
2024-07-12 |
2026-01-15 |
Blossomhill Therapeutics, Inc. |
Spirocyclic kras inhibitors for treating disease
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026035945A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
|
|
WO2026035947A1
(en)
|
2024-08-07 |
2026-02-12 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
CN119751476B
(zh)
*
|
2025-03-05 |
2025-06-03 |
苏州共康医药科技有限公司 |
螺环类化合物及其在医药上的应用
|